LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, for LNZ100 for the treatment of presbyopia, a condition ...

LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

The NDA submission for the treatment of presbyopia is supported by the positive data results from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not ...

(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.

Leerink Partnrs lifted their FY2028 EPS estimates for LENZ Therapeutics in a research report issued on Tuesday, October 15th.